摘要：第22届国际骨髓瘤学会（IMS）年会将于2025年9月17-20日在加拿大多伦多举行。国际骨髓瘤学会致力于汇聚从事骨髓瘤研究的临床和试验研究者，在全球范围内推动多发性骨髓瘤领域的教育、临床研究（包括诊断和治疗）以及会议的开展。国际骨髓瘤学会年会作为骨髓瘤领域的
第22届国际骨髓瘤学会（IMS）年会将于2025年9月17-20日在加拿大多伦多举行。国际骨髓瘤学会致力于汇聚从事骨髓瘤研究的临床和试验研究者，在全球范围内推动多发性骨髓瘤领域的教育、临床研究（包括诊断和治疗）以及会议的开展。国际骨髓瘤学会年会作为骨髓瘤领域的权威年度会议，聚焦基础研究、临床前研究及临床研究三大方向。今年，中国专家共有5篇研究入选Oral Presentations，83篇研究入选Poster Presentations，下面紧随小编步伐，一睹中国专家们的风采！
摘要号 标题 第一作者 及单位 PA-021 First-in-Human Study of GPRC5D-Targeted CAR T-cell Therapy CT071 with an Accelerated Manufacturing Process for the Treatment of Relapsed/Refractory Multiple Myeloma Lina Jin，上海长征医院 PA-029 Long Term Follow-Up of Zevor-Cel in Patients with Relapsed/Refractory Multiple Myeloma 傅琤琤，苏州大学附属第一医院 PA-055 CAR-TscmCells as anEffective ImmuneTreatment to Multiple Myeloma Patients Zhaoyun Liu，天津医科大学总医院 PA-056 CAC-MM-001: Anti-BCMACAR-T Therapy Followed by Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities Yuntong Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所） PA-065 Real-World Outcomes of Equecabtagene Autoleucel, the First Fully Human BCMA-Targeted CAR-T Therapy, in 150 Patients with Multiple Myeloma (MM): A Multicenter Experience from China Jin Lu，北京大学人民医院 PA-066 Kinetic Characteristics of T Cells in CAR-T Therapy for Multiple Myeloma: A Real-World Analysis 蔡真，浙江大学医学院附属第一医院 PA-095 Efficacy and Safety of CAR-T Therapy in CNS-MM Weiwei Tian，山西白求恩医院 PA-105 CART–ASCT–CART2 Sandwich Regimen as Frontline Therapy: A Phase II Trial in Patients with Primary Plasma Cell Leukemia Jingyu Xu，中国医学科学院血液病医院（中国医学科学院血液学研究所） PA-106 BCMACAR T-Cell Therapy in Newly Diagnosed Transplant-ineligible Multiple Myeloma: An Open Label, Single-arm, Phase 2 Study (CAREMM-001) Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所） PA-107 Impact of Frailty Tools on Outcomes in Myeloma: MRP and Simplified Index Predict Survival but Differ in Infection Risk Stratification Shaoli Zhang，山西白求恩医院 PA-108 A Comparison of Chemo-free Strategy with Plerixafor Plus G-CSF Versus High-Dose Cyclophosphamide Plus G-CSF as First-line PBSC Mobilization in Multiple Myeloma Patients: A Chinese Explorative Study Xiaoyan Han，浙江大学医学院附属第一医院 PA-110 Denosumab-Related Osteonecrosis of the Jaw in Patients with Multiple Myeloma: AChinese Single Center Retrospective Cohort Study Bin Chu，北京积水潭医院 PA-134 Factors Influencing the Outcome of Salvage Second Autologous Stem Cell Transplant in Relapsed Multiple Myeloma Yanjuan Li，中山大学附属第一医院 PA-137 Predicting Early Mortality Risk in Newly DiagnosedMultiple Myeloma PatientsChia-Jen Liu，台北荣民总医院
PA-157
Incidence and Risk Factors of Thromboembolic Events in Chinese Patients with Multiple Myeloma: A Single-Center Retrospective Cohort Study
Yunge Xu，北京协和医院
PA-160
Dialysis-Dependence is Associated with Poor Prognosis in Multiple Myeloma: a Multicenter Retrospective Cohort Study
Chenyun Wang，浙江大学医学院附属第一医院
PA-164
Serum Cholesterol Levels Demonstrate Dynamic Changes Following Autologous Hematopoietic StemCell Transplantation in Patients with Multiple Myeloma
Yuan Chen，北京积水潭医院
PA-173
Quantitative CD38 Expression and Clinical Response to Anti-CD38 Therapy in Multiple Myeloma: A Retrospective Cohort Analysis
Jianlin Hu，华中科技大学同济医学院附属同济医院
PA-177
Circulating Plasma Cells as an Independent Prognostic Marker in Newly Diagnosed Multiple Myeloma: Clinical Correlation and Immunophenotypic Insights
Yating Li，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-179
Verification and Optimization of VTE Risk Stratification System for Multiple Myeloma in China Based on Review Cohort
Yuexiao Liu，首都医科大学附属复兴医院
PA-180
Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis
Yuntong Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-198
Identification of a CAR–Derived Clone by NGS Based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma
Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-200
Performance and Additional Benefits of Matrix Assisted Laser Desorption/Ionization-Time-of Flight Mass Spectrometry in M-Protein Detection in Plasma Cell Disorders
Mengmeng Dong，浙江大学医学院附属第一医院
PA-201
Delayed and Sustained Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma
Jieqiong Zhou，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-202
Dynamic Changes in Cytogenetic Abnormalities Detected by Serial FISH Predict MRD Status and Outcomes in Multiple Myeloma
PA-217
Potential Roles of YBX1-MIF Axis in Promoting Bone Marrow Inflammation and Multiple Myeloma Progression
Mengping Chen，上海交通大学医学院附属仁济医院
PA-218
Bortezomib, Lenalidomide, and Dexamethasone Reverses the Inferior Prognostic Effect of KRAS Mutation in Patients with Newly-Diagnosed Multiple Myeloma
Lili Cheng，北京协和医院
PA-221
Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma
Jian Cui，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-225
Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma
Chenxing Du，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-226
MYC Copy Number Variation Detected by FISH Indicates a Similarly Poor Prognosis to MYC Rearrangement in Newly Diagnosed Multiple Myeloma
PA-235
Imbalance of Glycine Metabolism Contributes to Osteolysis in Multiple Myeloma
Cong Hu，中南大学肿瘤研究所
PA-243
Role and Mechanism of Multiple Myeloma Cells in Regulating Macrophage Polarization and the Antitumor Effect via ENO1
Zhaoyun Liu，天津医科大学总医院
PA-244
Targeting PIM-2 and PARP1 Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells Through NKG2D Binding
PA-245
Targeting Lactate Metabolism in Multiple Myeloma to Enhance CAR-T Cells Antitumor Function
PA-246
LILRB4 Drives Myeloid Immunosuppressive Microenvironment in Multiple Myeloma and Facilitates the Inferior Outcome of Patients
Lanting Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-272
Dual Roles of IRE1α Inhibition in Reversing Mitochondrial ROS-Induced CD8+ T Cell Senescence and Exerting Direct Anti-Tumor Effects in Multiple Myeloma
Yike Wan，上海交通大学医学院附属仁济医院
PA-273
Insights into Ubiquitination-Associated Genes in Multiple Myeloma: A Multi-Omics Mendelian Randomization Study
Jinuo Wang，浙江大学医学院附属第一医院
PA-276 Macrophages Promote Aberrant DNA Repair inMultiple Myeloma Via the CXCL5/CXCR2 AxisMengmeng Dong，浙江大学医学院附属第一医院 PA-277 Crosstalk Between m6A and H3K27ac via the YTHDC1-EP300 Feedback Loop Promotes Myelomagenesis Yifan Hou，浙江大学医学院附属第一医院 PA-278 NAMPT in Myeloma-Associated Macrophages Drives Drug Resistance through Mitochondrial Metabolic Reprogramming and Immune Evasion via the SIRT1/STAT3/SPP1 Axis Shunnan Yao，浙江大学医学院附属第一医院 PA-279 NEDD4-1-Mediated Ubiquitination of CCR7 Reprograms Macrophage Function and Enhances theraputic Sensitivity in Multiple Myeloma Xi Huang，浙江大学医学院附属第一医院 PA-280 The m5C-Binding Protein YB-1 Modulates Proteasome Inhibitors Resistance in Multiple Myeloma Via Epigenetic Modification Qiqi Shen，浙江大学医学院附属第一医院 PA-281 LILRB4 Drives Daratumumab Resistance in Multiple Myeloma via STAT3/PIM1 Activation and Lipid Metabolic Reprogramming of the Immune Microenvironment Xiaoyu Zhang，中国医学科学院血液病医院（中国医学科学院血液学研究所） PA-289 Enhanced Expression of TAGLN2 Predicts Negative
Prognosis in Multiple MyelomaMengping Chen，上海交通大学医学院附属仁济医院 PA-301 Enhancing Immunotherapy through Metabolic
Modulation in Humanized Multiple Myeloma MiceZhaoyun Liu，天津医科大学总医院
PA-302
Role and Mechanism of Pim-2 Kinase Inhibitors induced Immunogenic Cell Death in Multiple Myeloma
Zhaoyun Liu，天津医科大学总医院
PA-303
STAT3Inhibitors Inducing DNA DamageinMultiple Myeloma Cells and Enhancing the Anti-Tumor Effects of NK Cells
PA-323 LILRB4 Protects Multiple Myeloma Cells fromFerroptosis to Promote MM ProgressionYijie Wang，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-324
AKR1B1/NAT10 Mediate IL4I1 ac4C Modification to Regulate Tryptophan Metabolism and Promote Multiple Myeloma Proliferation
Rongfang Wei，中山大学附属第八医院
PA-325
RNF5-DNAJA1 Axis Dictates Selinexor Sensitivity of Multiple Myeloma
Yinyin Xu，重庆医科大学
PA-327
Carfilzomib, Pomalidomide, Dexamethasone ± Daratumumab Delivers Survival Benefit Regardless of Cytogenetic Risk in Early Relapsed Myeloma Patients-A Multi-Center, Prospective Real World Study in China
Fujing Zhang，北京协和医院
PA-328
Inhibition of DNA Damage Response Factor DNA PKcs-Mediated H2AX Phosphorylation Enhances Selinexor-Induced Anti-Multiple Myeloma Effects
Jinna Zhang，浙江大学医学院附属第一医院
PA-329
A Multi-Step Virtual Screening Framework Identifies Novel GPRC5D Inhibitors for Multiple Myeloma Therapy
Xi Chen，浙江大学医学院附属第一医院
PA-330
Prognostic Determinants of Overall Survival in POEMS Syndrome: A 7-Year Single-Center Retrospective Analysis
Yuhan Bao，华中科技大学同济医学院附属同济医院
PA-332
Clinical Study on the Efficacy and Safety of Aponermin Combined with Dexamethasone Based Regimen in Multidrug-Resistant Multiple Myeloma
Meilan Chen，中山大学附属第一医院
PA-352
The Study of Serum VEGF Expression in Different Types of Plasma Cell Diseases
Xiujin Li，中山大学附属第一医院
PA-353
Analysis of Clinical Characteristics and Prognostic Factors in Patients with Primary Plasma Cell Leukemia
Xiujin Li，中山大学附属第一医院
PA-354
Profound Decrease of dFLC After One Cycle Predicts Superior Outcome in Patients with AL Amyloidosis Treated with Daratumumab and Bortezomib-Based Regimens
Yang Liu，北京大学人民医院
PA-370
Efficacy and Safety of Daratumumab-Based Regimens in Light Chain Amyloidosis: A Retrospective Single-Center Study
Xinran Wang，华中科技大学同济医学院附属同济医院
PA-371
Integrative Clinical, Transcriptomic, and Immunohistochemical Characterization of Light Chain Amyloidosis in Bone Marrow and Cardiac Tissue
Chao-Hung Wei，台湾大学医学院附设医院
PA-377
Efficacy and Safety of Daratumumab, Lenalidomide, and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: A Single-Center Real-World Study in China
Li-Juan Fang，北京积水潭医院
PA-378
Steady-State Hematopoietic Cell Mobilization for Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy Versus IMiD-Based Induction Therapy: A Real- World Experience
鲍立，北京积水潭医院
PA-383
HSPA9 Contributes to Tumor Progression and Ferroptosis Resistance by Enhancing Usp14 Driven xCT Deubiquitination in Multiple Myeloma
Na Shen，江苏省人民医院
PA-384
Impact of CD34+ Cell Infusion Dose on Immune reconstitution and Survival in Multiple Myeloma after Autologous Stem Cell Transplantation
Lijuan Chen，江苏省人民医院
PA-400
D-VRd-based Dynamic Frailty-Tailored Therapy (DynaFiT-v2) in Elderly Patients with Newly Diagnosed Multiple Myeloma: a Prospective Study
Yingjie Zhang，吉林大学第一医院
PA-452
Interim Analysis of DARAVRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT as First Line in China
傅琤琤，苏州大学附属第一医院
PA-454
Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Newly Diagnosed Multiple Myeloma: Outcome and Safety Profile from a Multi-Center Real-World Experience
Yue Wu，首都医科大学附属复兴医院
PA-455
Dara-VCd in Newly Diagnosed Multiple Myeloma with Severe Renal Impairment: A Prospective Multicenter Single-Arm Study
Yang Yang，浙江大学医学院附属第一医院
PA-457
Early Identification of Patients with Multiple Myeloma Progressing within a Short-Term following Tandem Transplantation
Tongyong Yu，中山大学附属第一医院
PA-458
Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation on the Treatment of Multiple Myeloma: ASingle-Center Clinical Analysis on PFS
Hailong Yuan，新疆医科大学第一附属医院
PA-459
Efficacy and Safety of Ixazomib-Based Maintenance Therapy after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients: A Retrospective Analysis
PA-460
Efficacy and Safety of Biweekly/Weekly Ixazomib Dexamethasone Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma: A Multi-Center Study
Xiaoyan Han，浙江大学医学院附属第一医院
PA-461
Selinexor Combined Bortezomib, Lenalidomide, andDexamethasonefor NewlyDiagnosedMultiple Myeloma with High-Risk Cytogenetics Abnormalities: A Single-Arm, Multi-Center, Observational Clinical Study
Junjing Yin，青岛市立医院
PA-488
Efficacy and Safety of a China-Developed BCMA Targeted CAR-T Therapy (Eque-cel) in Plasma Cell Leukemia: Real-World Multicenter Experience
Dou Xuelin，北京大学人民医院
PA-511
Exploration of Efficacy for Frailty-Adjusted Dose Reduced Pcd Regimen in Relapsed/Refractory Multiple Myeloma
Weiwei Tian，山西白求恩医院
PA-513
Clinical Features and Management of GPRC5D related AE in Chinese Relapsed/Refractory Multiple Myeloma Patients Treated with Talquetamab: MonumenTAL-1 China Cohort Experience
安刚，中国医学科学院血液病医院（中国医学科学院血液学研究所）
PA-514
Real-World Treatment Patterns, Effectiveness, and Safety of Daratumumab-based Regimens in Chinese Patients with Multiple Myeloma: Final Analysis of the MMY4032 Study
王鲁群，山东大学齐鲁医院
PA-517
BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma
Lily Zhou，上海曜影医院
PA-518
Case Report: BCMA-targeting CAR T-cell Therapy Induces Complete and Durable Remission in Relapsed Extramedullary Plasmablastic Multiple Myeloma
Lily Zhou，上海曜影医院
PA-520
Efficacy and Safety of Low-frequency Daratumumab in Systemic Light-chain Amyloidosis
Donghua He，浙江大学医学院附属第一医院
PA-522
Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma
屈晓燕，江苏省人民医院
PA-531
Single-Cell Sequencing Reveals Transcriptional and Metabolic Divergence of Bone-Involved Multiple Myeloma
Dian Tong，江苏省人民医院
PA-533
Nutritional Status Indices on the Prognosis of Patients with Relapsed and Refractory Multiple Myeloma Treated with CAR-T Cell Immunotherapy
Peng Xu，徐州医科大学附属医院
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。
来源：灵科超声波
